Biogen and Xbrane in deal on rheumatoid arthritis targeting biosimilar 14-Feb-2022 By Jane Byrne Biogen Inc and Xbrane Biopharma AB have entered into a commercialization and licensing agreement on Xcimzane, a preclinical monoclonal antibody that is a proposed biosimilar referencing CIMZIA.